| Agustin | I was made redundant two months ago <a href=" http://www.dahlsafaris.com/exygra-online.pdf#fort ">buy exygra</a> Optimal doesn’t expect to repeat the stellar revenue growth next year but with shares trading on 16.5 times 2013 forecasts, falling to 15.7 times, it doesn’t need to. This is undoubtedly a high-risk investment. However the balance sheet strength allows growth through acquisition, so certainly one to watch. |
|